Document is current

Article History

Received: 5 December 2024

Accepted: 22 January 2025

First Online: 10 February 2025

Declarations

:

: Bruno Duarte has received honoraria for acting as a consultant and/or as a speaker for AbbVie, Pfizer, Janssen-Cilag, Leo-Pharma, Eli Lilly, Sanofi-Regeneron, Galderma, Almirall. He also was Principal Investigator in Clinical Trials supported by Abbvie and Sanofi. Pedro Mendes-Bastos has received honoraria for acting as a consultant and/or as a speaker for AbbVie, Apogee, Pfizer, Janssen-Cilag, Leo-Pharma, Novartis, Eli Lilly, Sanofi, Regeneron, Teva, L’Oreal, Pierre Fabre, Cantabria Labs, Bayer, Viatris, Organon, Evelo Biosciences, CS Labs. He also was Principal Investigator in Clinical Trials supported by AbbVie, Amgen, Biogen, Janssen, Pfizer, Novartis and Sanofi. Margarida Gonçalo has received honoraria for acting as a consultant or speaker for Abbvie, Almirall, AstraZeneca, Janssen-Cilag, Leo-Pharma, Lilly, Novartis, Pfizer, Sanofi, Takeda, and participated in clinical trials from Amgen, Biogen, Novartis, Sanofi-Regeneron. Tiago Torres declares the following conflicts of interest: AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Biocad, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, and Sandoz. Tiago Torres is also an Editorial Board member of Dermatology and Therapy. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Isabel Freitas and Vanda Marques are Pfizer employees. Joana Antunes, Filomena Azevedo and Martinha Henrique have nothing to disclose.

: Written informed consent was obtained prior to the subject entering the study (before initiation of study protocol-specified procedures). The final protocol, any amendments, and informed consent documentation were reviewed and approved by the institutional review board and/or independent ethics committee for each site participating in the study. The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor and following generally accepted research practices described in the Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE) as well as with the ethical principles stated in the Declaration of Helsinki.